Weiss Asset Management LP Acquires Shares of 28,680 Hims & Hers Health, Inc. $HIMS

Weiss Asset Management LP acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the first quarter, Holdings Channel.com reports. The institutional investor acquired 28,680 shares of the company’s stock, valued at approximately $595,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after acquiring an additional 1,407,651 shares in the last quarter. State Street Corp increased its holdings in Hims & Hers Health by 1.8% during the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after purchasing an additional 132,311 shares in the last quarter. Geode Capital Management LLC increased its holdings in Hims & Hers Health by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after purchasing an additional 608,950 shares in the last quarter. Invesco Ltd. raised its stake in shares of Hims & Hers Health by 62.7% in the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after purchasing an additional 1,600,004 shares during the last quarter. Finally, Marex Group plc raised its stake in shares of Hims & Hers Health by 162.2% in the fourth quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock worth $78,562,000 after purchasing an additional 1,496,707 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Stock Performance

HIMS stock opened at $30.23 on Tuesday. The firm has a market cap of $7.00 billion, a PE ratio of -335.84, a P/E/G ratio of 79.05 and a beta of 2.35. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The business has a 50 day moving average of $30.91 and a 200-day moving average of $26.25. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. During the same quarter last year, the business posted $0.20 earnings per share. The business’s revenue was up 3.8% compared to the same quarter last year. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 7,163 shares of the firm’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $36.49, for a total transaction of $261,377.87. Following the completion of the sale, the chief financial officer owned 284,321 shares in the company, valued at approximately $10,374,873.29. This trade represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David B. Wells acquired 48,400 shares of the stock in a transaction on Tuesday, May 26th. The stock was bought at an average cost of $24.23 per share, for a total transaction of $1,172,732.00. Following the transaction, the director owned 224,417 shares of the company’s stock, valued at approximately $5,437,623.91. This trade represents a 27.50% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders sold 83,126 shares of company stock worth $2,711,339. 11.76% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on HIMS shares. Truist Financial lifted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Friday. Weiss Ratings cut Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $25.00 price objective on shares of Hims & Hers Health in a report on Tuesday, May 5th. Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $31.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.